Seer (NASDAQ:SEER) & Evotec (NASDAQ:EVO) Financial Comparison

Evotec (NASDAQ:EVO) and Seer (NASDAQ:SEER) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Evotec and Seer”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97 million	0.75	-$117.12 million	N/A	N/A
Seer	$16.58 million	6.81	-$73.60 million	($1.22)	-1.67

Seer has lower revenue, but higher earnings than Evotec.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Evotec and Seer, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1	2	2	0	2.20
Seer	1	0	0	2	3.00

Evotec presently has a consensus target price of $3.00, indicating a potential upside of 58.73%. Seer has a consensus target price of $4.00, indicating a potential upside of 96.08%. Given Seer’s stronger consensus rating and higher probable upside, analysts clearly believe Seer is more favorable than Evotec.

Profitability

This table compares Evotec and Seer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Seer	-478.05%	-27.23%	-23.99%

Institutional & Insider Ownership

5.8% of Evotec shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 11.3% of Seer shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Evotec has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500.

Summary

Seer beats Evotec on 7 of the 13 factors compared between the two stocks.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.